In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $49.73, marking a -1.39% move from the previous day. This change lagged the S&P 500's daily loss of 0.66%. Meanwhile, the Dow lost 0.99%, and the Nasdaq, a tech-heavy index, lost 1.63%.
Coming into today, shares of the biopharmaceutical company had lost 18.6% in the past month. In that same time, the Medical sector lost 9.8%, while the S&P 500 lost 8.1%.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be February 4, 2019. On that day, BMY is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 19.12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.74 billion, up 5.41% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.78 per share and revenue of $22.46 billion, which would represent changes of +25.58% and +8.1%, respectively, from the prior year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.39% higher. BMY is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, BMY currently has a Forward P/E ratio of 13.34. For comparison, its industry has an average Forward P/E of 14, which means BMY is trading at a discount to the group.
Meanwhile, BMY's PEG ratio is currently 1.57. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.91 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 98, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
In the latest trading session, Bristol-Myers Squibb (BMY - Free Report) closed at $49.73, marking a -1.39% move from the previous day. This change lagged the S&P 500's daily loss of 0.66%. Meanwhile, the Dow lost 0.99%, and the Nasdaq, a tech-heavy index, lost 1.63%.
Coming into today, shares of the biopharmaceutical company had lost 18.6% in the past month. In that same time, the Medical sector lost 9.8%, while the S&P 500 lost 8.1%.
Wall Street will be looking for positivity from BMY as it approaches its next earnings report date. This is expected to be February 4, 2019. On that day, BMY is projected to report earnings of $0.81 per share, which would represent year-over-year growth of 19.12%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.74 billion, up 5.41% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $3.78 per share and revenue of $22.46 billion, which would represent changes of +25.58% and +8.1%, respectively, from the prior year.
Any recent changes to analyst estimates for BMY should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.39% higher. BMY is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, BMY currently has a Forward P/E ratio of 13.34. For comparison, its industry has an average Forward P/E of 14, which means BMY is trading at a discount to the group.
Meanwhile, BMY's PEG ratio is currently 1.57. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.91 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 98, which puts it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BMY in the coming trading sessions, be sure to utilize Zacks.com.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE